Navamedic ASA Reports Double-Digit Growth in Q3 2025
Navamedic ASA, a Nordic pharma company, delivered revenues of NOK 138.9 million in the third quarter of 2025, representing a 12.9% increase from Q3 2024.
The company's gross margin improved to 37.5%, compared to 37.1% in Q3 2024. Adjusted EBITDA amounted to NOK 11.3 million, up from NOK 8.6 million in 2024.
The revenue growth was driven by increases in all three business areas, including the Rx business area, which generated NOK 10.6 million in revenues from the dne business.
No additional statements were provided by the company.
Author's summary: Navamedic ASA sees double-digit growth in Q3 2025.
More News
- Elvish Yadav – Official Facebook Page Summary
- Evans scores 19 in UC Irvine's 73-60 win over UC Riverside
- Vandals Feast on Two Wins at UC Irvine Thanksgiving Classic
- Ashes 2025-26 - Ben Stokes
- Elvish Yadav calls himself husband material, says he has a softer side too
- Rida Tharana — Threads Profile
- CSU Northridge vs. UC Irvine Women’s Basketball: Free Live Stream, TV Channel, How to Watch
- Ben Stokes' gritty 36 keeps England's Ashes hopes alive
- Sonam Bajwa Joins Elvish Yadav At ‘Aukaat Se Bahar’ Screening, Netizens Want Them Together In A Project
- The Big West Men’s Basketball Notebook: Conference Play Begins with Bold Week